Q4 2024 Earnings Call Transcript March 20, 2025 ARS Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.52, ...

“Our momentum is highlighted by the steady increase in physician adoption, positive patient feedback, and growing payer coverage, which form a strong ... Systems, and TRICARE, with ongoing ...

President Trump axed security clearances and revoked access to classified information for several political figures on Friday ...

Cash Position & Operating Runway: As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments ...

ARS Pharmaceuticals Inc. (NASDAQ: SPRY) reported its fourth-quarter 2024 earnings, significantly surpassing analyst expectations with an EPS of $0.51 against a forecasted loss of $0.13. The ...

If you’re looking for a provider, it’s important to understand the different types of TRICARE providers you can see. The type ...

“Our momentum is highlighted by the steady increase in physician adoption, positive patient feedback, and growing payer coverage, which form a strong foundation for long-term success. With a ...

ARS Pharmaceuticals Inc. (NASDAQ: SPRY) reported its fourth-quarter 2024 earnings, significantly surpassing analyst expectations with an EPS of $0.51 against a forecasted loss of $0.13. The company ...

U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...